Browse the glossary using this index
Special | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
Urząd Rejestracji Produktów Leczniczych, Wyrobow Medycznych i Produktów Biobójczych
Utility, or usefulness, is the (perceived) ability of something to satisfy needs or wants. In health economics, utilities measure the strength of patient preferences. For example, how important various factors are to patients, such as symptoms, pain, and psychological health. The impact of new treatments on those factors, and therefore on quality of life (QoL), can then be calculated. This is a common approach used by health technology assessment (HTA) bodies, which advise on whether treatments should be funded by (for example) government health departments.
Vaccines are biological preparations developed from modified versions of the micro-organisms that cause a disease. Vaccines improve or convey immunity to particular diseases, usually in an effort to prevent or cure disease.
Scientific validity refers to how well a measurement, test or study measures what it is intended to measure.
Valstybinė vaistų kontrolės tarnyba
In gene therapy, a vector is a method of delivering DNA into patients' cells. A common vector used in gene therapy is the adenovirus. A gene therapy vector must be customised to attempt treatment of a particular disorder. To be successful, a vector must target the right cells, the gene it is carrying must be activated in the patient, and it must avoid harmful side effects.
Vulnerable participants or populations
Vulnerable participants or populations are individuals or groups of individuals who are unable to give informed consent to take part in a clinical trial, such as children or people affected by mental health conditions, or who may come under pressure from others to take part. It also includes people whose willingness to volunteer in a clinical trial may be unduly influenced by their expectations of taking part.
If a trial is to include people from vulnerable populations, special attention should be paid to protecting their well-being, both by the investigators and the ethics committee that reviews the trial protocol.
Wash out period
In a clinical trial, this refers to a break in ongoing treatment. It is quite often used in crossover trials where a set period is defined before switching to a new medicine. In this period the levels of the previous medicine in the body and the effects should be reduced to zero.
Whole Genome Sequencing
Whole genome sequencing (WGS) is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time. Great progress in the speed at which genomes can be sequenced, in the number of genomes that can be sequenced at the same time, and in the reducing the cost of sequencing has had a huge impact on medical research and medicines development.
High-throughput genome sequencing technologies have largely been used as a research tool and are currently being introduced into clinical practice. In the future of personalised medicine, whole genome sequencing will be an important tool to guide treatments.
World Health Organisation
World Health Organisation (WHO) http://www.who.int/en/"